Otrivine Blocked Nose Relief (Xylometazoline Hydrochloride)

Otrivine Blocked Nose Relief contains a nasal decongestant that acts on the upper‑respiratory tract to reduce swelling.

• Common cold: temporary relief of nasal blockage caused by viral upper‑respiratory infection.
• Acute sinusitis: reduction of mucosal edema to improve sinus drainage.
• Allergic rhinitis: alleviation of congestion associated with seasonal or perennial allergies.
• Nasal polyposis (post‑operative care): helps maintain airway patency after surgical intervention.

• Xylometazoline hydrochloride selectively stimulates alpha‑adrenergic receptors on the smooth muscle of nasal blood vessels, causing vasoconstriction. This reduces blood flow to the nasal mucosa, decreasing edema and opening the nasal passages, which improves airflow and eases the sensation of congestion.

Side effects are generally mild and related to local nasal irritation.

Common Side Effects

• Nasal burning or stinging sensation.
• Mild headache.
• Dryness of the nasal mucosa.
• Sneezing.
• Transient taste disturbance.

Serious or Rare Side Effects

• Persistent nasal irritation or ulceration.
• Severe headache or facial pain.
• Hypertension exacerbation in susceptible individuals.
• Rebound congestion with prolonged use (>5‑7 days).
• Allergic reaction such as rash, itching or swelling.

Before using Otrivine Blocked Nose Relief, consider the following safety points:

• Age restriction: not for children under 6 years without medical advice.
• Duration limit: avoid use longer than 5‑7 consecutive days to prevent rebound congestion.
• Cardiovascular conditions: use cautiously in patients with hypertension or heart disease.
• Pregnancy and lactation: consult a healthcare professional before use.
• Drug interactions: inform the prescriber of any concurrent nasal or systemic decongestants.
• Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Xylometazoline may interact with other agents that affect vascular tone or blood pressure.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of excessive vasoconstriction.
• Systemic alpha‑adrenergic agonists (e.g., phenylephrine): additive hypertensive effect.

Moderate Interactions (Monitor Closely)

• Other nasal decongestants: increased risk of rebound congestion.
• Antihypertensive medications: may blunt blood‑pressure‑lowering response.
• Tricyclic antidepressants: potential for enhanced vasoconstriction.
• Herbal preparations containing ephedrine or pseudoephedrine: additive sympathomimetic activity.